Can Interim 18F-FDG PET or Diffusion-Weighted MRI Predict End-of-Treatment Outcome in FDG-Avid MALT Lymphoma After Rituximab-Based Therapy?: A Preliminary Study in 15 Patients.

Mayerhoefer, Marius E

Can Interim 18F-FDG PET or Diffusion-Weighted MRI Predict End-of-Treatment Outcome in FDG-Avid MALT Lymphoma After Rituximab-Based Therapy?: A Preliminary Study in 15 Patients. [electronic resource] - Clinical nuclear medicine Nov 2016 - 837-843 p. digital

Publication Type: Journal Article

1536-0229

10.1097/RLU.0000000000001395 doi


Aged
Antineoplastic Agents--therapeutic use
Breast Neoplasms--diagnostic imaging
Diffusion Magnetic Resonance Imaging
Eye Neoplasms--diagnostic imaging
Female
Fluorodeoxyglucose F18
Humans
Image Processing, Computer-Assisted
Immunotherapy
Lacrimal Apparatus Diseases--diagnostic imaging
Lung Neoplasms--diagnostic imaging
Lymph Nodes--diagnostic imaging
Lymphoma, B-Cell, Marginal Zone--diagnostic imaging
Male
Middle Aged
Multidetector Computed Tomography
Positron Emission Tomography Computed Tomography
Positron-Emission Tomography
Prognosis
Prospective Studies
Radiopharmaceuticals
Remission Induction
Rituximab--therapeutic use
Soft Tissue Neoplasms--diagnostic imaging
Splenic Neoplasms--diagnostic imaging
Stomach Neoplasms--diagnostic imaging
Treatment Outcome